Biotech · Private company
EQRx International, Inc.
Track this companyFree. Adds EQRx International, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Aumolertinib monotherapyPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- Osimertinib monotherapyPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- aumolertinibPhase 1 · Severe Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- sugemalimabExtranodal NK/T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung CancerPHASE3 · TERMINATED · started Dec 14, 2022ClinicalTrials.gov NCT05493501 · fetched Nov 12, 2026
- An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143PHASE1 · COMPLETED · started Mar 30, 2022ClinicalTrials.gov NCT05199610 · fetched Nov 12, 2026
- An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)NO_LONGER_AVAILABLEClinicalTrials.gov NCT05131438 · fetched Nov 12, 2026